These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 16151468)

  • 1. Coexistence of AML1/RUNX1 and BCR-ABL point mutations in an imatinib-resistant form of CML.
    Corm S; Biggio V; Roche-Lestienne C; Laï JL; Yakoub-Agha I; Philippe N; Nicolini FE; Facon T; Preudhomme C
    Leukemia; 2005 Nov; 19(11):1991-2. PubMed ID: 16151468
    [No Abstract]   [Full Text] [Related]  

  • 2. A novel Bcr-Abl splice isoform is associated with the L248V mutation in CML patients with acquired resistance to imatinib.
    Gruber FX; Hjorth-Hansen H; Mikkola I; Stenke L; Johansen T
    Leukemia; 2006 Nov; 20(11):2057-60. PubMed ID: 17008892
    [No Abstract]   [Full Text] [Related]  

  • 3. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.
    Hochhaus A; Kreil S; Corbin AS; La Rosée P; Müller MC; Lahaye T; Hanfstein B; Schoch C; Cross NC; Berger U; Gschaidmeier H; Druker BJ; Hehlmann R
    Leukemia; 2002 Nov; 16(11):2190-6. PubMed ID: 12399961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
    Wei Y; Hardling M; Olsson B; Hezaveh R; Ricksten A; Stockelberg D; Wadenvik H
    Ann Hematol; 2006 Dec; 85(12):841-7. PubMed ID: 17006667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Second hematologic response and disappearance of the ABL gene mutant clone by cessation of imatinib in a CML patient with resistance to imatinib].
    Murase K; Matsunaga T; Takeuchi N; Fujimi A; Takimoto R; Terui T; Hirayama Y; Niitsu Y
    Rinsho Ketsueki; 2004 Sep; 45(9):1028-32. PubMed ID: 15510830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia.
    Roche-Lestienne C; Laï JL; Darré S; Facon T; Preudhomme C
    N Engl J Med; 2003 May; 348(22):2265-6. PubMed ID: 12773665
    [No Abstract]   [Full Text] [Related]  

  • 7. Evidence for D276G and L364I Bcr-Abl mutations in Ph+ leukaemic cells obtained from patients resistant to Imatinib.
    Piazza RG; Magistroni V; Gasser M; Andreoni F; Galietta A; Scapozza L; Gambacorti-Passerini C
    Leukemia; 2005 Jan; 19(1):132-4. PubMed ID: 15510211
    [No Abstract]   [Full Text] [Related]  

  • 8. Double Philadelphia-chromosome: a resistance factor on the imatinib mesylate therapy for chronic myeloid leukemia.
    Otero L; Ornellas MH; Dobbin J; de Souza Fernandez T
    Int J Lab Hematol; 2008 Aug; 30(4):346-8. PubMed ID: 18665834
    [No Abstract]   [Full Text] [Related]  

  • 9. Roots of clinical resistance to STI-571 cancer therapy.
    Barthe C; Cony-Makhoul P; Melo JV; Mahon JR
    Science; 2001 Sep; 293(5538):2163. PubMed ID: 11567109
    [No Abstract]   [Full Text] [Related]  

  • 10. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.
    Soverini S; Colarossi S; Gnani A; Rosti G; Castagnetti F; Poerio A; Iacobucci I; Amabile M; Abruzzese E; Orlandi E; Radaelli F; Ciccone F; Tiribelli M; di Lorenzo R; Caracciolo C; Izzo B; Pane F; Saglio G; Baccarani M; Martinelli G;
    Clin Cancer Res; 2006 Dec; 12(24):7374-9. PubMed ID: 17189410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Analysis of ABL tyrosine kinase point mutations in imatinib treated chronic myelogenous leukemia patients].
    Qin YZ; Liu YR; Li JL; Ruan GR; Zhu HH; Jiang Q; Fu JY; Lu Y; Chang Y; Li LD; Huang XJ; Chen SS; Qiu JY
    Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(45):3186-9. PubMed ID: 16405837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib.
    Khorashad JS; Anand M; Marin D; Saunders S; Al-Jabary T; Iqbal A; Margerison S; Melo JV; Goldman JM; Apperley JF; Kaeda J
    Leukemia; 2006 Apr; 20(4):658-63. PubMed ID: 16467863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP).
    Nicolini FE; Corm S; Lê QH; Sorel N; Hayette S; Bories D; Leguay T; Roy L; Giraudier S; Tulliez M; Facon T; Mahon FX; Cayuela JM; Rousselot P; Michallet M; Preudhomme C; Guilhot F; Roche-Lestienne C
    Leukemia; 2006 Jun; 20(6):1061-6. PubMed ID: 16642048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer research. Why some leukemia cells resist STI-571.
    Marx J
    Science; 2001 Jun; 292(5525):2231-3. PubMed ID: 11423629
    [No Abstract]   [Full Text] [Related]  

  • 15. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
    Burchert A; Wang Y; Cai D; von Bubnoff N; Paschka P; Müller-Brüsselbach S; Ottmann OG; Duyster J; Hochhaus A; Neubauer A
    Leukemia; 2005 Oct; 19(10):1774-82. PubMed ID: 16136169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytogenetic and molecular mechanisms of resistance to imatinib.
    Hochhaus A
    Semin Hematol; 2003 Apr; 40(2 Suppl 2):69-79. PubMed ID: 12783379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. E355G mutation appearing in a patient with e19a2 chronic myeloid leukaemia resistant to imatinib.
    Bennour A; Beaufils N; Sennana H; Meddeb B; Saad A; Gabert J
    J Clin Pathol; 2010 Aug; 63(8):737-40. PubMed ID: 20702476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back.
    von Bubnoff N; Peschel C; Duyster J
    Leukemia; 2003 May; 17(5):829-38. PubMed ID: 12750693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Roots of clinical resistance to STI-571 cancer therapy.
    Hochhaus A; Kreil S; Corbin A; La Rosée P; Lahaye T; Berger U; Cross NC; Linkesch W; Druker BJ; Hehlmann R; Gambacorti- Passerini C; Corneo G; D'Incalci M
    Science; 2001 Sep; 293(5538):2163. PubMed ID: 11569495
    [No Abstract]   [Full Text] [Related]  

  • 20. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
    Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.